Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer
Jennifer R. Diamond, Carlos Becerra, Donald Richards, Alain C. Mita, Cynthia R. Osborne, Joyce O’Shaughnessy, Chun Zhang, Randall Henner, Ann M. Kapoun, Lu Xu, Bob Stagg, Shailaja Uttamsingh, Rainer K. Brachmann, Azeez Farooki, Monica Mita
Topics & Concepts
MedicineInternal medicineBreast cancerClinical endpointMetastatic breast cancerOncologyBiomarkerPaclitaxelCancerGastroenterologyResponse Evaluation Criteria in Solid TumorsTriple-negative breast cancerPhases of clinical researchChemotherapyClinical trialBiochemistryChemistryHER2/EGFR in Cancer ResearchCancer Treatment and PharmacologyWnt/β-catenin signaling in development and cancer